Quest Diagnostics Incorporated
DGX
Helyezés a részvények között
#931
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus,... Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Részvényárfolyam
$236.69
Utolsó szinkronizálás: 2026-10-20
Piaci kapitalizáció
$26.12B
Változás (1 nap)
0.80%
Változás (1 év)
28.19%
Ország
US
Kereskedés Quest Diagnostics Incorporated (DGX)
Kategória
Healthcare
Quest Diagnostics Incorporated (DGX) nyeresége
Nyereség ekkor: Jun 2026 TTM: $1.42B
Quest Diagnostics Incorporated legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi nyeresége $1.42B. 2024 évben a vállalat $1.19B nyereséget ért el, növekedés a 2023 év nyereségéhez, amely $1.16B volt. Az ezen az oldalon megjelenített nyereség a kamatok és adók előtti eredmény, azaz EBIT.
Quest Diagnostics Incorporated nyereségtörténete 2000 és 2026 között
Nyereség az év végén
| Év | Nyereség | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $1.42B | 4.34% |
| 2025 | $1.36B | 13.90% |
| 2024 | $1.19B | 3.29% |
| 2023 | $1.16B | -9.62% |
| 2022 | $1.28B | -52.22% |
| 2021 | $2.68B | 36.65% |
| 2020 | $1.96B | 72.90% |
| 2019 | $1.13B | 22.35% |
| 2018 | $926.00M | -10.10% |
| 2017 | $1.03B | -5.16% |
| 2016 | $1.09B | -1.54% |
| 2015 | $1.10B | 29.92% |
| 2014 | $849.00M | -37.02% |
| 2013 | $1.35B | 26.17% |
| 2012 | $1.07B | 24.77% |
| 2011 | $856.30M | -27.70% |
| 2010 | $1.18B | -3.55% |
| 2009 | $1.23B | 20.50% |
| 2008 | $1.02B | 11.68% |
| 2007 | $912.40M | -11.70% |
| 2006 | $1.03B | 13.49% |
| 2005 | $910.45M | 9.02% |
| 2004 | $835.13M | 13.19% |
| 2003 | $737.80M | 36.03% |
| 2002 | $542.38M | 63.07% |
| 2001 | $332.60M | 65.49% |
| 2000 | $200.98M | 0.00% |
Hasonló cégek vagy versenytársak nyeresége
| Vállalat | Nyereség | Nyereségkülönbség | Ország |
|---|---|---|---|
| $7.61B | 436.22% |
US
|
|
| $4.76B | 235.59% |
US
|
|
| $-252.70M | -117.81% |
US
|
|
| - | - |
CN
|
|
| $1.66B | 16.84% |
US
|
